Intervention News

Pharmacists are one of the most accessible health care providers and singularly well positioned to lead efforts in integrating pharmacogenomics testing to improve medication-related outcomes.

Among adults with apparent resistant hypertension, treatment with renal denervation improved left ventricular hypertrophy and LV ejection fraction but had no significant effect on diastolic function, according to a new meta-analysis.

An initiative in Michigan successfully reduced patient, physician and staff exposure to procedural radiation during percutaneous coronary intervention, and may be generalizable in other states, researchers reported.

G. Alain Cribier, MD, FACC, FESC, long considered a father of interventional cardiology and a mentor to many, died Feb. 16 at age 79 years, the American College of Cardiology announced.

Efemoral Medical announced the FDA granted breakthrough device status to its vascular scaffold system for treatment of de novo or restenotic lesions of the infrapopliteal arteries in patients with chronic limb-threatening ischemia.

An FDA advisory panel voted 13-1 that the benefits of a transcatheter edge-to-edge repair device outweigh any risks in adults with symptomatic severe tricuspid regurgitation, despite no improvement in hard endpoints seen in a pivotal trial.

Adults younger than 60 years with severe aortic stenosis are increasingly opting for transcatheter aortic valve replacement despite data suggesting poorer 5-year survival compared with surgical AVR, researchers reported.

W. L. Gore and Associates announced the FDA approved of its low-profile balloon expandable stent for treatment of iliac artery de novo or restenotic lesions with reference vessel diameters of 5 to 13 mm and lesion length up to 110 mm.

AngioDynamics announced its 225 cm radial access catheter for use with the company’s atherectomy system received FDA 510(k) clearance for the treatment of peripheral artery disease.

The FDA approved the first transcatheter tricuspid valve replacement system for the treatment of symptomatic severe tricuspid regurgitation despite optimal medical therapy.